NOTABLE LABS, LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 USD | -15.54% |
|
+31.58% | -33.86% |
Presenter SpeechDror Harats (Executives)Good afternoon, everybody. And [Foreign Language]. It ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.25
USD
Average target price
8
USD
Spread / Average Target
+540.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.86% | 11.27M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +0.73% | 22.25B | |
| -13.14% | 22.09B | |
| -8.00% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- NTBL Stock
- News Notable Labs, Ltd.
- Transcript : Vascular Biogenics Ltd. - Special Call
